QMS Q2 FY27 revenue rises 18% while quarterly PAT falls 32%
Key highlights
- QMS Q2FY27 net revenue from operations increased 18% year on year to Rs 52.5 crore.
- QMS Q2FY27 PAT declined 32% year on year to Rs 2.4 crore.
- QMS EBITDA margin fell to 12.4% in Q2FY27 from 15.5% in Q2FY26.
- QMS short-term borrowings rose to Rs 81.2 crore at September 2026 from Rs 68.5 crore at March 2026.
powered by IRIS

QMS Medical Allied Services Limited reported Q2FY27 net revenue from operations of Rs 52.5 crore, up 18% year on year, while profit after tax (PAT) fell 32% to Rs 2.4 crore. Earnings declined as earnings before interest, tax, depreciation and amortisation (EBITDA) margin fell to 12.4% from 15.5%, alongside lower operating cash flow in the September 2026 comparison.
Know QMS Medical Allied Services inside out
Results, valuation, peers and who's buying, in one view.
Why did QMS profit decline despite revenue growth in Q2FY27?
QMS reported higher revenue but lower earnings in Q2FY27, with EBITDA declining 6% to Rs 6.5 crore from Rs 6.9 crore despite net revenue rising by Rs 7.8 crore to Rs 52.5 crore. Profit before tax fell 32% to Rs 3.3 crore from Rs 4.8 crore, while PAT declined by Rs 1.2 crore from Rs 3.6 crore to Rs 2.4 crore.
The year-on-year cost movement shows where the revenue gain did not reach profit. Cost of goods sold fell to Rs 21.6 crore from Rs 25.6 crore, but employee expenses increased to Rs 12.6 crore from Rs 3.0 crore and other expenses rose to Rs 11.8 crore from Rs 9.2 crore. Finance cost increased to Rs 1.9 crore from Rs 1.4 crore, while depreciation increased to Rs 1.6 crore from Rs 0.9 crore.
How did QMS margins change in Q2FY27?
QMS's EBITDA margin declined by 3.1 percentage points year on year to 12.4% in Q2FY27 from 15.5% in Q2FY26, while PAT margin fell by 3.4 percentage points to 4.6% from 8.0%. The Rs 52.5 crore revenue base therefore produced a smaller operating-profit and net-profit share than in the comparable quarter.
Sequentially, QMS revenue fell 8% from Rs 56.9 crore in Q1FY27 to Rs 52.5 crore in Q2FY27, while EBITDA decreased 21% from Rs 8.3 crore to Rs 6.5 crore. EBITDA margin was 14.6% in Q1FY27 and 12.4% in Q2FY27, while PAT margin moved from 7.0% to 4.6%. PAT declined 38% quarter on quarter from Rs 4.0 crore.
The first-half comparison also showed revenue growing faster than profit. H1FY27 revenue increased 20% to Rs 109.4 crore from Rs 91.2 crore in H1FY26, while EBITDA grew 11% to Rs 14.8 crore from Rs 13.4 crore. EBITDA margin fell to 13.6% from 14.7%, and PAT margin declined to 5.8% from 7.4% as H1FY27 PAT decreased 5% to Rs 6.4 crore.
What changed in QMS's balance sheet and cash flow?
QMS short-term borrowings increased by Rs 12.7 crore to Rs 81.2 crore at September 2026 from Rs 68.5 crore at March 2026. Total current liabilities rose to Rs 108.3 crore from Rs 92.2 crore, while total equity declined to Rs 101.1 crore from Rs 109.9 crore. Reserves and surplus decreased by Rs 9.2 crore to Rs 71.6 crore over the same dates.
Working-capital balances were also higher at September 2026. Trade receivables rose by Rs 6.9 crore to Rs 71.9 crore from Rs 65.0 crore, and inventories increased by Rs 1.6 crore to Rs 47.5 crore from Rs 45.9 crore. Cash and bank balance declined to Rs 80 lakh from Rs 1.2 crore, while total assets increased to Rs 217.9 crore from Rs 211.0 crore.
The presentation reports net cash from operations of Rs 4 crore at September 2026, compared with Rs 19 crore at March 2026. Cash flow from investing activities was negative Rs 12 crore and cash flow from financing activities was Rs 8 crore in the September 2026 column. It reported a net decrease of Rs 40 lakh in cash and cash equivalents, with closing cash and cash equivalents of Rs 1 crore.
Got a follow-up? Ask IRIS
What plans has QMS disclosed after Q2FY27?
QMS signed a binding memorandum of understanding dated September 25, 2026, for the proposed 100% acquisition of Pune-based diagnostics and analytical deep-tech company BeamOptics Scientific. Consideration may be paid through cash, a share swap or a combination, based on an independent valuation. The transaction remains subject to mutual fulfilment of terms and conditions and National Company Law Tribunal approval of the composite scheme involving Health Care At Home India Private Limited.
According to QMS, BeamOptics brings research and development, compliance and manufacturing capabilities, while QMS brings sales, marketing and distribution. The presentation lists seven patents filed by BeamOptics, with two commercial and six in rollout, as well as Central Drugs Standard Control Organisation test licences and MD-5 manufacturing licences. Management said the proposed acquisition would expand QMS into diagnostic technology and value-added healthcare products.
Management is also pursuing a composite scheme to consolidate QMS's Patient Support Program and Healthcare Services businesses, together with the Patient Support Program division of Health Care At Home India Private Limited, into subsidiary Saarathi Healthcare Private Limited. Management said the combined platform would manage more than 160 active programs, serve more than 1.2 million patients and deploy more than 2,000 healthcare professionals across more than 35 cities. These are management-stated post-integration measures rather than reported Q2FY27 results.
Conclusion
QMS increased Q2FY27 revenue to Rs 52.5 crore, but lower EBITDA, PAT and margins meant that the additional sales did not translate into higher quarterly earnings. The September 2026 balance sheet comparison also showed increases in receivables, inventories and short-term borrowings, while net cash from operations was Rs 4 crore compared with Rs 19 crore in the presentation's March 2026 column.
Next, investors can watch the disclosed approvals and conditions for the BeamOptics Scientific acquisition and the composite scheme involving Saarathi Healthcare Private Limited and Health Care At Home India Private Limited. Management has said its immediate priority is seamless operational integration with no disruption to patient care or the pharmaceutical product business; subsequent results can show the effects on revenue, margins, receivables and cash flow.


